

Attorney Docket No.: **ABLE-0020**  
Inventors: **Urbaniak and Barker**  
Serial No.: **09/857,097**  
Filing Date: **July 27, 2001**  
Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of the Claims:**

Claim 1 (currently amended): A method for the prevention of alloimmunisation of a subject against a rhesus protein selected from the group consisting of RhD, RhC, Rhc, RhE, Rhe and Rh50 comprising administering to the subject an immunologically effective epitope of a rhesus protein selected from the group consisting of RhD, RhC, Rhc, RhE, Rhe and Rh50 protein.

Claim 2 (currently amended): A method for the immunosuppression of a response elicited by alloimmunisation of a subject against a rhesus protein selected from the group consisting of RhD, RhC, Rhc, RhE, Rhe and Rh50 comprising administering to the subject an immunologically effective epitope of a rhesus protein selected from the group consisting of RhD, RhC, Rhc, RhE, Rhe and Rh50 protein.

Claim 3-4 (canceled)

Claim 5 (previously presented): A method according to claim 1 or 2 wherein the epitope is selected from at least

Attorney Docket No.: ABLE-0020  
Inventors: Urbaniak and Barker  
Serial No.: 09/857,097  
Filing Date: July 27, 2001  
Page 3

one of SEQ ID numbers 2, 5, 6, 11, 12, 14, 28, 29, 31, 38, 39, 44, 47, 50, 51, 66, 75, 77, 78, 79, 81 and 84.

Claim 6 (previously presented): A method according to claim 5 wherein the epitope is SEQ ID NO:79.

Claim 7 (currently amended): A method according to claim 1 or 2 wherein the epitope or immunoreactive derivative is artificially synthesised.

Claim 8 (previously presented): A method of claim 1 or 2 wherein the epitope is disposed in a pharmacologically acceptable vehicle.

Claim 9-11 (canceled)

Claim 12 (previously presented): A method according to claim 8 wherein the vehicle is selected such that the composition is in an injectable, oral, rectal, topical or spray-uptake form.

Claim 13-15 (canceled)

Claim 16 (previously presented): A method according to claim 8 wherein the pharmaceutically acceptable vehicle is

Attorney Docket No.: **ABLE-0020**  
Inventors: **Urbaniak and Barker**  
Serial No.: **09/857,097**  
Filing Date: **July 27, 2001**  
Page 4

adapted for transdermal or transmucosal administration or wherein said vehicle is a formulation with an enteric coating for oral administration.

Claim 17-18 (canceled)

Claim 19 (currently amended): A method for the tolerisation of a patient who may become alloimmunised against a rhesus protein selected from the group consisting of RhD, RhC, Rhc, RhE, Rhe and Rh50 comprising administering an epitope selected from a RhD, RhC, Rhc, RhE ~~or Rhe~~ , Rhe or Rh50 protein or selected from at least one of SEQ ID numbers 2, 5, 6, 11, 11A, 12, 14, 28, 29, 31, 38, 39, 44, 47, 50, 51, 66, 75, 77, 78, 79, 81 and 84, and a pharmaceutically acceptable vehicle therefor.

Claim 20 (currently amended): A method for the immunosuppression of an alloimmunised patient against a rhesus protein selected from the group consisting of RhD, RhC, Rhc, RhE, Rhe and Rh50 comprising administering an epitope selected from a RhD, RhC, Rhc, RhE ~~or Rhe~~ , Rhe or Rh50 protein or selected from at least one of SEQ ID numbers 2, 5, 6, 11, 11A, 12, 14, 28, 29, 31, 38, 39, 44, 47, 50, 51, 66, 75, 77, 78, 79, 81 and 84, and a pharmaceutically acceptable vehicle therefor.

Attorney Docket No.: **ABLE-0020**  
Inventors: **Urbaniak and Barker**  
Serial No.: **09/857,097**  
Filing Date: **July 27, 2001**  
Page 5

Claim 21 (previously presented): A method according to either claim 19 or 20 wherein the vehicle is adapted for transdermal or transmucosal administration.

Claim 22-23 (canceled)